Latest News

Two New Studies on Benzoyl Peroxide Provide Reassuring Data on Safety


 

Two new studies focusing on the safety of benzoyl peroxide (BP)–containing acne products with typical everyday use found no reason for concern about either high blood levels of benzene, a breakdown product of BP, or cancer risk.

Earlier this year, controversy erupted after an independent lab Valisure petitioned the US Food and Drug Administration (FDA) to recall acne products with BP because it found extremely high levels of the carcinogen benzene. In the research, the lab directors contended that the products can form over 800 times the “conditionally restricted” FDA concentration limit of 2 parts per million (ppm) of benzene, with both prescription and over-the-counter (OTC) products affected. The issue, according to the lab’s report, is one of degradation, not contamination; BP can decompose into benzene. Exposures to benzene have been linked with a higher risk for leukemia and other blood cancers.

Benzene in container Kittisak Kaewchalun/iStock/Getty Images

(“Conditionally restricted” means that the maximum of 2 ppm only applies to a drug product in which the use of benzene is unavoidable in order to produce a drug product with a significant therapeutic advance, according to FDA guidance.)

Critics of the report questioned the method used to test the products, calling for more “real-world” use data, and said the temperature used may not be what is expected with everyday use.

Now, both new studies are reassuring about the safety of the products, John Barbieri, MD, MBA, assistant professor of dermatology at Harvard Medical School and director of the Advanced Acne Therapeutics Clinic at Brigham and Women’s Hospital, Boston, said in a telephone interview. He was a coauthor of both studies. A leading dermatologist not involved in the new research reviewed the findings and agreed.

John Barbieri, MD, MBA, assistant professor of dermatology, Harvard Medical School, and director of the Advanced Acne Therapeutics Clinic at Brigham and Women's Hospital, Boston Brigham and Women's Hospital

Dr. John Barbieri

One study using data from the National Health and Nutrition Examination Survey compared blood levels of benzene between 14 people who had used BP products and 65 people without a history of BP product use, finding no difference between the groups .

The other, much larger study analyzed electronic health records of more than 27,000 patients with acne using BP products, comparing them with more than 27,000 controls who did not use the products. The patients were followed for 10 years after the use of BP products began, and no increased risk for cancer, either blood cancers or solid tumors, was found.

The studies were recently published in the Journal of the American Academy of Dermatology.

“Both studies are well done,” said Henry W. Lim, MD, former chair of the Department of Dermatology and senior vice president for academic affairs at Henry Ford Health, Detroit. Dr. Lim, a former president of the American Academy of Dermatology, reviewed the results of both studies.

Dr. Henry W. Lim a former chair of the department of dermatology at Henry Ford Health System, Detroit. Dr. Lim

Dr. Henry W. Lim

“These studies indicate that [a] report of detection of benzene in [BP] products exposed to high temperature does not have any relevant clinical significance, both in terms of blood levels and in terms of internal cancer,” Dr. Lim said. “This is consistent with the clinical experience of practicing dermatologists; no internal side effects have been observed in patients using [BP products].”

Pages

Recommended Reading

MDedge Daily News: How smartphones could battle oral cancer
MDedge Hematology and Oncology
iPLEDGE allows at-home pregnancy tests during pandemic
MDedge Hematology and Oncology
Novel acne drug now under review at the FDA
MDedge Hematology and Oncology
Daily Recap 6/17
MDedge Hematology and Oncology
Increased risk of meningioma with cyproterone acetate use
MDedge Hematology and Oncology
Spironolactone not linked to increased cancer risk in systematic review and meta-analysis
MDedge Hematology and Oncology
Study Finds No Increased Cancer Risk With Spironolactone
MDedge Hematology and Oncology